1. Introduction {#sec1}
===============

Breast cancer (BC) is one of the most usual malignant tumors among women worldwide which results in high rates of morbidity and mortality \[[@B1], [@B2]\]. Over the past two decades, the incidence rate of BC has been increasing constantly \[[@B3], [@B4]\]. Accumulating evidence showed that genes, proteins, and several pathways are involved in the occurrence and progression of BC, and the precise molecular mechanisms are still unclear. To date, surgery is the first choice for early-stage BC patients, but most clinically diagnosed advanced BC patients are forced to accept chemotherapy \[[@B5]\], radiotherapy \[[@B6]\], endocrine therapy \[[@B7]\], or biotherapy \[[@B8]\]. The management of the disease is primarily to improve quality of life (QOL) and prevent disease from recurring.

Although targeted add-on therapy with monoclonal antibodies such as trastuzumab or pertuzumab has been proved to be efficacious in specific types of BC, the high costs still slowed down the widespread use in developing countries of the world. Therefore, effective and affordable adjunct therapies are needed. Aidi injection (ADI) is a compound preparation injection of Chinese herbs (Z52020236, CFDA), which is composed of the extracts from *Panax ginseng* C. A. Mey, *Astragalus propinquus* Schischkin, *Acanthopanax senticosus* (Rupr. Maxim.) Harms, and *Mylabris phalerata* Pallas \[[@B9]\]. According to a study on chemical constituents in the Aidi injection, 22 chemical components were detected and isolated \[[@B10]\]. These compounds are astragaloside, ginsenoside, eleutheroside, coniferin, etc. Previous studies showed that ADI could significantly improve the clinical response and QOL in patients with non-small cell lung cancer (NSCLC) \[[@B11]\] and gastric cancer. Several clinical trials also revealed that ADI could reduce the toxicity of chemotherapy in breast cancer \[[@B12], [@B13]\]. However, the efficacy on BC has been inconclusive due to a lack of summary. Therefore, we performed a systematic review and meta-analysis. Findings from such a study may help determine whether to use ADI as an add-on therapy on BC.

2. Methods {#sec2}
==========

2.1. Protocol and Registration {#sec2.1}
------------------------------

The protocol of the present review was registered in the International Platform of Registered Systematic Review and Meta-Analysis Protocols (Inplasy, <https://inplasy.com/>) and was reported in accordance with PRISMA \[[@B14]\] (Preferred Reporting Items for Systematic Reviews and Meta-Analyses). The registration number is INPLASY202040170, and the DOI number is 10.37766/inplasy2020.4.0170.

2.2. Search Strategy {#sec2.2}
--------------------

We conducted an online search for trials from inception up to Jan 2020, in PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>), EMBASE (<http://www.embase.com>), CNKI (<http://www.cnki.net/>), SinoMed (<http://www.sinomed.ac.cn/>), and the Cochrane Central Register of Controlled Trials (CENTRAL) (<http://onlinelibrary.wiley.com/cochranelibrary/>) with the search terms "(Breast Neoplasms \[MH\] OR breast neoplasm^*∗*^\[TIAB\] OR breast carcinoma^*∗*^\[TIAB\] OR breast tumor^*∗*^\[TIAB\] OR breast tumor^*∗*^\[TIAB\] OR breast cancer^*∗*^\[TIAB\]) AND (Aidi injection\[TIAB\])," following the demonstration of Cochrane handbook (ZM and LH). In addition, we performed handsearches of the references of all identified articles and relevant reviews (GJ).

2.3. Study Selection {#sec2.3}
--------------------

Eligible clinical trials were defined based on the following criteria: (1) randomized controlled trials of advanced breast cancer (parallel groups or cross-over design); (2) age \>18 years; (3) intervention with Aidi injection as an add-on therapy compared with conventional chemotherapy; (4) reported ORR and adverse events or at least one additional outcome.

Exclusion criteria: (1) animal or cell research; (2) observational studies; (3) reviews, letter to the editor, or case reports; (4) duplicates.

Two authors, respectively, reviewed the titles and abstracts (LW and CY). If there were discrepancies between the present reviewers, another author (QZ) was consulted to reach a consensus as the third investigator.

2.4. Data Collection Process {#sec2.4}
----------------------------

We extracted data from each selected study, including the name of the first author, publication year, geographical location, study design, cases, participants, doses, outcomes, and statistical methods. We followed the recommendations for reporting by the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines \[[@B14]\] (PRISMA). The quality of individual records was assessed according to the Cochrane handbook.

2.5. Outcomes {#sec2.5}
-------------

The primary endpoint was the overall response rate \[[@B15]\] (complete remission + partial remission, ORR) and the disease control rate (complete remission + partial remission + stable disease, DCR). Secondary outcomes included the QOL, immune cells, and adverse events.

2.6. Statistical Analysis {#sec2.6}
-------------------------

Review Manager software (version 5.3; Cochrane Collaboration, Oxford, UK) was used for estimating risks of bias of included studies, data analysis, and plotting. The sensitivity analysis and the publication bias test were performed using the *R* language. *I*^2^ and chi-square tests were used to estimate heterogeneity. If *P* \> 0.1 or *I*^2^ \< 40%, the fixed-effect model meta-analysis was performed. When there was a high degree of heterogeneity, a random-effect analysis was used. For each group, the Aidi injection group was compared to placebo or other active chemotherapy. Weighted mean difference (WMD) or standard mean difference (SMD) was used for analysis of continuous data, and the rate ratio (RR) was calculated for the dichotomous variable, respectively.

3. Results {#sec3}
==========

3.1. Study Description and Risk of Bias {#sec3.1}
---------------------------------------

By using the search strategy mentioned above, a total of 24 trials were identified after duplicated records were removed. After screening the title and the abstracts, we retrieved the full texts of 20 records, of which 14 were ultimately included in our analysis involving 1006 participants totally. The details of the exclusions are shown in [Figure 1](#fig1){ref-type="fig"}. In total, 14 trials were included in the present study, and the characteristics of the trials are shown in [Table 1](#tab1){ref-type="table"}. Most of the included trials showed relatively low to medium quality. The Cochrane handbook \[[@B28]\] was used to evaluate the risk of bias for RCTs ([Figure 2](#fig2){ref-type="fig"}). The treatments of the 14 included articles were ADI plus chemotherapy.

3.2. Primary Outcomes {#sec3.2}
---------------------

Ten trials reported ORR and DCR as the main outcome. The pooled effect showed that ADI increased ORR in BC patients as an add-on therapy with little heterogeneity (*RR* = 1.14, 95% CI 1.03--1.27; chi^2^ = 5.71, *P*=0.77; *I*^2^ = 0%; [Figure 3](#fig3){ref-type="fig"}). DCR in BC patients could not be improved by ADI as an add-on therapy (*RR* = 1.02, 95% CI 0.97--1.07; chi^2^  = 6.55, *P*=0.6; *I*^2^ = 0%; [Figure 4](#fig4){ref-type="fig"}).

3.3. Secondary Outcomes {#sec3.3}
-----------------------

ADI plus chemotherapy improved the KPS score in BC patients compared with chemotherapy alone (MD = 3.26, 95% CI 1.74--4.78; chi^2^ = 0.4, *P*=0.94; *I*^2^ = 0%; [Figure 5](#fig5){ref-type="fig"}). There were no improvements on CD3%, CD4%, and CD8%. The CD4/CD8 ratio was higher while treated with ADI with a high heterogeneity (MD = 0.32, 95% CI 0.07--0.58; chi^2^ = 48.88, *P* ≤ 0.01; *I*^2^ = 88%). NK% data showed the same trend with CD4/CD8. Serum tumor markers CEA and CA153 were decreased while treated with ADI, but only one trial was involved ([Table 2](#tab2){ref-type="table"}).

3.4. Adverse Events {#sec3.4}
-------------------

ADI decreased the numbers of myelosuppression in advanced BC patients as an add-on therapy (*RR* = 0.69, 95% CI 0.52--0.92; chi^2^  = 17.95, *P*=0.003; *I*^2^ = 72%; [Figure 6](#fig6){ref-type="fig"}). AST, ALT, *γ*-GT, and CK-MB were all decreased by ADI treatment. No other side effects were recorded during the studies. Details are shown in [Table 3](#tab3){ref-type="table"}.

3.5. Publication Bias {#sec3.5}
---------------------

No obvious publication bias was found through the funnel plot (ORR) ([Figure 7](#fig7){ref-type="fig"}). Egger\'s test showed the result of the linear regression test of the funnel plot asymmetry: *t* = 1.4319, *df* = 8, and *P* value = 0.1901. The result indicated that there was no publication bias.

3.6. Sensitivity Analysis {#sec3.6}
-------------------------

The sensitivity was evaluated through excluding the poor and overestimated studies about the main outcome ORR. The analysis indicated that the result of the pooled effect size had good stability ([Figure 8](#fig8){ref-type="fig"}).

4. Discussion {#sec4}
=============

BC is commonly discovered among women worldwide of which the incidence rate has been increasing constantly. Advanced breast cancer patients do not have many choices but to accept chemotherapy. During a long-term clinical practice, traditional Chinese medicines have played important roles in treating some types of tumors. However, the molecular mechanisms are poorly discovered. ADI is a compound injection of Chinese herbs which is widely used in treating malignant tumors including breast cancer.

The present meta-analysis suggested that based on the existed evidence, treatment with ADI significantly changed the ORR of patients with advanced BC but did not obviously increase the DCR. There were also improvements on quality of life, and an increase in the KPS score was observed. To some extent, the immune system was improved because the CD4/CD8 ratio and NK cells were higher while treated with ADI. However, CD3, CD4, and CD8 did not change because of one study \[[@B26]\] which induced high heterogeneity and showed totally reversed effect to other studies. The participant\'s age, intervention, and duration were not significantly different from others\'. ADI seemed to be safe for patients. ADI decreased the numbers of myelosuppression, AST, ALT, *γ*-GT, and CK-MB in BC patients as an add-on therapy. No obvious publication bias was found through the funnel plot (ORR).

The mechanism of ADI on BC was suggested that ADI significantly inhibited the proliferation of MCF-7 cells in a dose-dependent manner \[[@B29]\] and the miRNA might serve as potentially therapeutic targets. The modulation of miRNA expression is an important mechanism of ADI inhibiting breast cancer cell growth. Another experiment reported that ADI could inhibit proliferation, promote apoptosis and necrosis of tumor cells, and significantly reduce the cell diameter \[[@B30]\]. But, the research is limited, so more studies should better be involved in and discover the underlying mechanisms.

Several limitations of this meta-analysis should be mentioned. First, the quality of included trials was relatively low, some of which did not report the details of blinding and allocation concealment. This might induce bias of the results. Little research studies provided survival data. Previous studies showed good effect of ADI on patients with BC which may be a potential drug as an adjunct therapy. However, additional high-quality RCTs and larger sample sizes may lead to more reliable results. Second, the records of survival terms were seldomly reported, and we were not able to calculate the overall survival of specific year. Furthermore, the therapeutic duration and designs were not identical, which may lead to heterogeneity. Subgroup analysis was not performed because included articles were limited and difficult to be grouped.

5. Conclusion {#sec5}
=============

In summary, this meta-analysis suggested that based on the existing evidence, treatment with ADI significantly changed the ORR of patients with advanced BC and improved their quality of life with few side effects. More randomized trials involving larger samples should be considered, and detailed mechanisms are needed to be uncovered.
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###### 

Characteristics of included trials.

  Trials                         Design   No. of cases T/C   Age T/C                          KPS T/C                      TNM         Treatment                               Control      Outcomes
  ------------------------------ -------- ------------------ -------------------------------- ---------------------------- ----------- --------------------------------------- ------------ ----------------------------
  Yumeng \[[@B16]\]              RCT      24/26              55.08 ± 10.32/54.12 ± 10.75      86.25 ± 5.76/87.50 ± 5.52    I--IV       Aidi 100 ml/d/1--7 q 21d + CEF or CAF   CEF or CAF   SAS, SDS, QLQC30, ORR, AEs
  Weiming \[[@B13]\]             RCT      39/40              46.73 ± 14.2/45.98 ± 15.78       \>50\#                       III-IV      Aidi 100 ml/d/1--8 q 21d + CEF          CEF          ICs, QoL, BMs, AEs
  Yonghong \[[@B12]\]            RCT      64/64              46.7 ± 20.3                      \#                           I--IV       Aidi 100 ml/d/1--8 q 21d + CEF          CEF          ICs, AEs
  Liwang et al. \[[@B17]\]       RCT      78/62              52.5 (24∼76)/51.2 (20∼70)^*∗*^   \#                           I--IV       Aidi 100 ml/d/1--14 + CEF or CAF        CEF or CAF   ICs
  Mei and Li \[[@B18]\]          RCT      23/23              52 (36∼64)^*∗*^                  \#                           I--III      Aidi 100 ml/d/1--7 q 21d + CEF          CEF          VEGF
  Sandi et al. \[[@B19]\]        RCT      26/22              42.27 ± 6.32/42.23 ± 6.7         84.23 ± 5.78/84.55 ± 5.96    IIA--IIIC   Aidi 60 ml/d/1--4 q 14d + TC-P          TC-P         ORR, QoL, AEs
  Chuanhui et al. \[[@B20]\]     RCT      24/28              57.21 ± 3.52/55.66 ± 3.43        \#                           IIB--IIIB   Aidi 80 ml/d/1--15 q 21d + TAC          TAC          ORR, ICs
  Zhuorong et al. \[[@B21]\]     RCT      30/26              42.47 ± 7.85/42.54 ± 8.10        83.67 ± 6.15/84.62 ± 5.82    II-III      Aidi 60 ml/d/1--4 q 14d + AC-T          AC-T         ORR, QoL, AEs
  Xiangguo and Lin \[[@B22]\]    RCT      28/20              36.2 ± 3.6/37.5 ± 4.2            72.87 ± 4.69/71.89 ± 5.03    I--IIIA     Aidi 100 ml/d/1--10 q 21d + CTF         CTF          ORR, QoL, AEs
  Ling and Xiaoge \[[@B23]\]     RCT      44/44              42 (32∼63)/48 (31∼65)            \#                           I--IV       Aidi 100 ml/d/1--15 q 28d + NP          NP           ORR, DCR, TTP, AEs
  Xiangqiand Shaobo \[[@B24]\]   RCT      32/20              46.2 ± 2.6/44.5 ± 3.2            70.78 ± 4. 40/71.19 ± 4.53   I--IIIA     Aidi 100 ml/d/1--10 q 21d + CEF         CEF          ORR, QoL, AEs
  Wenjuan \[[@B25]\]             RCT      30/30              48.4/47.6                        \#                           III-IV      Aidi 100 ml/d/1--10 q 21d + CAF         CAF          ORR, ICs, QoL
  Zhenzhen \[[@B26]\]            RCT      50/50              45^*∗*^                          \#                           II-III      Aidi 100 ml/d/1--14 q 21d + CAF         CAF          ORR, ICs, QoL, AEs
  Ling \[[@B27]\]                RCT      31/28              54.2 (32∼69)/53.5 (31∼70)        \#                           II--IV      Aidi 50 ml/d/1--15 q 21d + NT           NT           ORR, ICs, QoL, AEs

BC: breast cancer; T: treatment; C: control; ORR: overall response rate; DCR: disease control rate; TTP: time to progression; AE: adverse events; QoL: quality of life; BM: blood marker; IC: immune cell; SAS: Self-Rating Anxiety Scale; SDS: Self-Rating Depression Scale; QLQC30: Quality Of Life Questionnaire Core 30; CF: cardiac function; ECG: electrocardiogram; CK: creatinine kinase; CEF: cytoxan, epirubicin, and 5-fluorouracil; CAF: cytoxan, adriamycin, and 5-fluorouracil; TC-P: theprubicin, cytoxan, and paclitaxel; TAC: theprubicin, adriamycin, and cytoxan; AC-T: adriamycin, cytoxan, and theprubicin; CTF: cytoxan, theprubicin, and 5-fluorouracil; NT: navelbine and theprubicin. ^*∗*^Data were expressed as medium and interquartile range (IQR). \#Details not reported.

###### 

Secondary outcomes.

  Outcomes        No. of trials          Heterogeneity             Effect size with 95% CI   Z with *P* value      
  --------------- ---------------------- ------------------------- ------------------------- --------------------- ----------------------
  Immune cells                                                                                                     
   CD3%           7^12,13,18,21,26−28^   514.87 (*P* \< 0.00001)   99                        3.71 (−3.85∼11.27)    0.96 (*P*=0.34)
   CD4%           7^12,13,18,21,26−28^   1302.78 (*P* \< 0.0001)   100                       6.67 (−2.71∼16.06)    1.39 (*P*=0.16)
   CD8%           7^12,13,18,21,26−28^   747.57 (*P* \< 0.00001)   99                        −0.97 (−7.54∼5.6)     0.29 (*P*=0.77)
   CD4/CD8        7^12,13,18,21,26−28^   48.88 (*P* \< 0.00001)    88                        0.32 (0.07∼0.58)      2.5 (*P*=0.01
   NK%            4^12,13,18,26^         29.39 (*P* \< 0.00001)    90                        5.54 (4.60∼6.47)      11.64 (*P* \< 0.001)
                                                                                                                   
  Tumor markers                                                                                                    
   CEA            1^13^                  ---                       ---                       −2.39 (−3.99∼−0.79)   2.93 (*P*=0.003)
   CA153          1^13^                  ---                       ---                       −3.06 (−5.17∼−0.95)   2.85 (*P*=0.004)

###### 

Safety of ADI.

  Outcomes           No. of trials   Heterogeneity             Effect size with 95% CI   Z with *P* value         
  ------------------ --------------- ------------------------- ------------------------- ------------------------ ----------------------
  Hepatic function                                                                                                
   AST               3^22,23,25^     112.69 (*P* \< 0.00001)   98                        −31.21 (−47.06∼−15.36)   3.86 (*P*=0.001)
   ALT               3^22,23,25^     4.86 (*P*=0.09)           59                        −4.04 (−5.57∼−2.51)      5.16 (*P* \< 0.0001)
   *γ*-GT            2^23,25^        0.08 (*P*=0.78)           0.0                       −24.59 (−27.78∼−21.40)   15.1 (*P* \< 0.0001)
                                                                                                                  
  Cardiac function                                                                                                
   CK-MB             2^22,23^        0.64 (*P*=0.42)           0.0                       −4.04 (−5.91∼−2.17)      4.23 (*P* \< 0.0001)
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